Neurocrine Biosciences (NASDAQ:NBIX) Given New $185.00 Price Target at Needham & Company LLC

Neurocrine Biosciences (NASDAQ:NBIX) had its price target trimmed by Needham & Company LLC from $187.00 to $185.00 in a report issued on Thursday,Benzinga reports. The firm currently has a buy rating on the stock.

Several other equities research analysts have also recently issued reports on NBIX. Piper Sandler boosted their price objective on shares of Neurocrine Biosciences from $175.00 to $179.00 and gave the company an “overweight” rating in a research report on Wednesday, October 29th. Truist Financial dropped their price objective on Neurocrine Biosciences from $172.00 to $169.00 and set a “buy” rating on the stock in a research note on Thursday, January 8th. UBS Group reduced their price objective on Neurocrine Biosciences from $188.00 to $178.00 and set a “buy” rating on the stock in a report on Friday, January 23rd. Citigroup upped their target price on Neurocrine Biosciences from $175.00 to $203.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Finally, JPMorgan Chase & Co. decreased their price objective on Neurocrine Biosciences from $179.00 to $177.00 and set an “overweight” rating for the company in a report on Monday, January 12th. Fifteen equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $177.56.

Neurocrine Biosciences Price Performance

Shares of NASDAQ:NBIX opened at $123.10 on Thursday. The business has a 50 day simple moving average of $140.77 and a two-hundred day simple moving average of $140.46. The firm has a market capitalization of $12.27 billion, a PE ratio of 26.42, a price-to-earnings-growth ratio of 0.64 and a beta of 0.31. Neurocrine Biosciences has a 1 year low of $84.23 and a 1 year high of $160.18.

Insiders Place Their Bets

In other news, Director Leslie V. Norwalk sold 5,000 shares of the stock in a transaction on Monday, December 15th. The stock was sold at an average price of $152.23, for a total value of $761,150.00. Following the completion of the transaction, the director owned 7,429 shares of the company’s stock, valued at approximately $1,130,916.67. This represents a 40.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director George J. Morrow sold 15,000 shares of the firm’s stock in a transaction on Tuesday, November 25th. The shares were sold at an average price of $143.37, for a total value of $2,150,550.00. Following the transaction, the director directly owned 7,068 shares in the company, valued at $1,013,339.16. This trade represents a 67.97% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 61,966 shares of company stock valued at $8,625,166. Corporate insiders own 4.80% of the company’s stock.

Hedge Funds Weigh In On Neurocrine Biosciences

Large investors have recently bought and sold shares of the stock. Federation des caisses Desjardins du Quebec lifted its stake in shares of Neurocrine Biosciences by 0.6% in the 4th quarter. Federation des caisses Desjardins du Quebec now owns 104,107 shares of the company’s stock worth $14,765,000 after acquiring an additional 633 shares during the period. DRW Securities LLC bought a new stake in Neurocrine Biosciences during the fourth quarter worth approximately $399,000. Brooklyn Investment Group lifted its position in Neurocrine Biosciences by 55.2% in the fourth quarter. Brooklyn Investment Group now owns 4,572 shares of the company’s stock worth $657,000 after purchasing an additional 1,627 shares during the period. Cibc World Markets Corp bought a new position in Neurocrine Biosciences during the 4th quarter valued at $488,000. Finally, Commonwealth Equity Services LLC increased its position in shares of Neurocrine Biosciences by 1.2% during the 4th quarter. Commonwealth Equity Services LLC now owns 14,501 shares of the company’s stock valued at $2,057,000 after purchasing an additional 178 shares during the period. Institutional investors and hedge funds own 92.59% of the company’s stock.

Neurocrine Biosciences News Summary

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Analysts continue to show conviction in the long‑term story — several firms reiterated Buy/Outperform ratings and high price targets, signaling confidence in the Ingrezza franchise and pipeline potential. TipRanks: Bank of America reiterates Buy
• Positive Sentiment: Recent analyst upgrades/raises include Citigroup lifting its price target (to $204) and Wedbush nudging its target higher — evidence that some investors still see significant upside. Benzinga: Citi/Wedbush price target moves
• Positive Sentiment: Underlying commercial results were strong: full‑year 2025 net product sales and year‑over‑year revenue growth reinforce that Ingrezza remains a durable cash generator. PR Newswire: Q4 and FY2025 results
• Neutral Sentiment: Revenue came in roughly in line with expectations (~$805M), so top‑line growth isn’t the main driver of the decline — the market is reacting to profit/guidance details. MarketBeat: Earnings report & transcript
• Neutral Sentiment: Analyst reactions are mixed: several firms trimmed price targets modestly (RBC, BMO, Needham adjustments) while most maintained Buy/Outperform ratings — creates volatility but not a broad sell consensus. TipRanks: Mixed PT adjustments
• Negative Sentiment: EPS missed expectations — adjusted EPS reported below consensus — which, combined with cautious near‑term commentary, triggered selling pressure. MarketBeat: EPS miss details
• Negative Sentiment: Market commentary flagged “disappointing Ingrezza guidance” as a key catalyst for the decline — investors appear to have expected a stronger 2026 sales outlook. Benzinga: Analysts on Ingrezza guidance
• Negative Sentiment: Trading showed heavy volume and reports noted insider selling activity — both amplify downside momentum in the near term. QuiverQuant: Stock falls, insider selling

About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.